Optionale Produktanalyse
Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
The Procter & Gamble Company's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $340.1B | |
|---|---|---|
| Revenue (ttm) | 87.9B | |
| Net income (ttm) | 15.7B | |
| EPS (ttm) | $6.64 | |
| Shares out | 2.3B | |
| P/E (trailing) | 23.9x | |
| P/E (forward) | 21.1x | |
| Dividend | $4.35 (2.75%) | |
| Volume | 3,382,574 | |
| Beta | 0.38 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2026-06-30 | Trend |
| Revenue | $80.19B | $82.01B | $84.04B | $84.28B | $87.03B | +2.1% |
| Gross profit | $38.03B | $39.25B | $43.19B | $43.12B | $43.67B | +3.5% |
| Operating income | $17.81B | $18.13B | $18.55B | $20.45B | $19.75B | +2.6% |
| Net income | $14.74B | $14.65B | $14.88B | $15.97B | $16.05B | +2.1% |
| EPS (diluted) | $5.81 | $5.90 | $6.02 | $6.51 | $6.62 | +3.3% |
| EBITDA | $21.24B | $21.77B | $22.58B | $23.92B | $21.25B | +0.0% |
| R&D | $2.00B | $2.00B | $2.00B | $2.10B | $2.10B | +1.2% |
| SG&A | $20.22B | $21.11B | $23.31B | $22.67B | $23.92B | +4.3% |
Recent company headlines from major financial publishers.
The base case is modest compounding, not a sharp reacceleration. A miss against either annual revenue anchor would disconfirm it by FY2028.
Upside requires FY2028 earnings to meet the forecast, FY2026 cash generation to persist, and the FY2024-to-FY2026 decline in diluted shares to continue. A miss against the FY2028 forecast or weaker operating cash would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | $151 | $163 | $180 | $204 | $244 |
| 6.0% | $131 | $138 | $146 | $158 | $173 |
| 7.0% | $117 | $121 | $126 | $133 | $141 |
| 8.0% | $107 | $110 | $113 | $117 | $122 |
| 9.0% | $99.4 | $102 | $104 | $107 | $110 |
Upcoming earnings date and setup when available.
Das Rating, das die veröffentlichte Research-Ausgabe des jeweiligen Monats trug. Ein Rating vergleicht den Kurs zum Analysezeitpunkt mit dem Fair Value; es ist kein Nachweis, ob die Einschätzung zutraf.
| Jahr | Jan | Feb | Mär | Apr | Mai | Jun | Jul | Aug | Sep | Okt | Nov | Dez |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |